Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (September 2023)
24 slides from Sona Nanotech's investor presentation, September 2023
Slide 1: A Therapy to Eliminate Certain Tumors Without the Collateral Damage
A Therapy to Eliminate Certain Tumors Without the Collateral Damage of Chemo, Radiation or Surgery September 2023 sonanano.com CSE: SONA | OTCQB: SNANF
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking information under Actual results may differ materially from those set forth in applicable securities law. All information that addresses this presentation due to risks and uncertainties affecting Sona activities or developments tha
Slide 3: Sona Nanotech at a Glance
Sona’s GNR Advantages Sona Nanotech at a Glance BIOCOMPATIBLE GNR Uniquely Biocompatible: • Patented(1), biocompatible proprietary gold GOLD NANOROD TECHNOLOGY Sona surfactant uses no CTAB nanoparticle technology • Equally as effective at heat transfer as CTAB-based GNRs. • Therapies: What are Gold
Slide 4: Therapies: Sona Gold Nanorod Technology
01 BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Sona Gold Nanorod ("GNR") Technology Uniquely biocompatible Unlocking of in-vivo medical applications potential GNR-Based by developing ‘Targeted Hyperthermia Therapy’ Therapies sonanano.com 4 CSE: SONA | OTCQB: SNANF
Slide 5: Sona Has Engineered the Right 'Gene Pool' to Pursue Its Cancer Therapy
Sona Has Engineered the Right ‘Gene Pool’ to Pursue Its Cancer Therapy Board Mark Lievonen Walter Strapps PhD Neil Fraser Dr. Michael Gross Jim Megann Chairman Director Director Director Director o Led vaccine maker Sanofi- o CEO of Khosla Ventures o Led Medtronic Canada for ~20 o Surgeon and corpor
Slide 6: Treatment for Rectal Cancer is Often Limited to Risky Surgery
Treatment for Rectal Cancer is Often Limited to Risky Surgery, Resulting in a Poor Quality of Life Wait and Short course Long course Watch chemo chemo • Lack of structural complexity • Lack of structural complexity If no success: (“Total mesorectal excision”) Area removed Too often, there is no choi
Slide 7: Sona is Developing a Therapy to Shrink Tumors Without Surgery, Chemo or Radiation
Sona is Developing a Therapy to Shrink Tumors Without Surgery, Chemo or Radiation with Positive Results to Date Day 0 Day 19 Day 59 Immediately after Tumor mass gone “Durable cure” treatment, (same mouse in all images) large multi-lobed tumor Popp, M.K., Oubou, I., Shepherd, C., Nager, Z., Anderson,
Slide 8: Targeted Hyperthermia Therapy Will Use Current Technology to Apply IR Light
‘Targeted Hyperthermia Therapy’ (“THT”) Will Use Current Technology to Apply IR Light to GNR-saturated Tumors A Two-step Therapy Conceptual Step 1. Step 2. Inject Biocompatible Shine IR Light Tuned Gold Nanorods to 850nm on tumour Nanoparticles shown in a red Sona’s 2.0 light device to be blood cell
Slide 9: THT's Hyperthermia Approach Designed to Kill Cancer Cells Selectively
THT’s ‘Hyperthermia’ Approach is Designed to Kill Cancer Cells Selectively, and Not Harm Healthy Tissue Steak As An Analogy For Human Tissue Typical Approach: Sona’s THT Approach: “ABLATION” “HYPERTHERMIA” (> 55°C) (~44°C) Medium-well Blue Rare Goal is to avoid the damage of ‘blasting’ heat indiscri
Slide 10: Gold Nanorods are Highly Efficient at Converting IR Light Into Heat
Heat Kills Cancer Cells and Gold Nanorods are Highly Efficient at Converting Harmless IR Light Energy into Heat Simulated Tumor Heating Using IR Light) 120 110 100 Meatball with nanorods Temp (°F) 90 Meatball with no nanorods 80 70 An IR Light Shining on A Simulated Tumor 60 0 50 100 150 200 250 300
Slide 11: Hyperthermia Brings Multiple, Incremental Physiological Benefits
Plus, ‘Hyperthermia’ Brings Multiple, Incremental Physiological Benefits Shrinks tumors Causes cancer cell death Kills cancer stem cells Often drug- Targeted Hyperthermia resistant Therapeutic Heat 44°C / 111°F Increases tumor perfusion Could enhance drug therapy Stimulates immune system Targets met
Slide 12: Goal to 'Steal' Market Share From Chemo, Radiation and Resection Surgeries
Goal to ‘Steal’ Market Share From Chemo, Radiation Prospective and Resection Surgeries for Rectal Cancer Stage 1 Stage 2 Stage 3 Stage 4 Cancer Stage Local Regional Lymph Node Metastatic Characteristics • Lack of structural complexity Watch and CRT/Resectio Current Standard of Care CRT/Resection CRT
Slide 13: The Risks of Commercialization of THT May Be More Operational than Technical
The Risks of the Commercialization of THT May Be More Operational than Technical Previously Done/Approved: Sona Needs to Do: - Using heat to treat cancer 1. Deliver infrared light through an endoscope - Photothermal treatment using that can monitor temperature in real time infrared light devices 2.
Slide 14: Compelling Prospective Market and Potential to Save Thousands of Lives
Compelling Prospective Market…and Potential to Save Thousands of Lives Annually Cancer Rectal Colon Esophageal Head & Neck Total Cases per Year 46,000 106,000 21,000 67,000 238,000 • Lack of structural complexity Treatable by THT 28,000 40,000 9,000 30,000 106,000 Deaths Per Year 18,000 34,000 17,00
Slide 15: Progress Updates
Progress Updates: GNR ‘GMP’ Manufacturing: Pre-clinical Trial Plan: - Increased yield via tangential flow filtration - Two CRO’s recommendations for: (“TFF”) • Lack of structural complexity - ofSafety • Lack studies structural complexity - Significantly reduced free surfactant levels - Biocompatibil
Slide 16: Diagnostics
02 Lateral Flow Assays (LFA’s) BIOCOMPATIBLE as diagnostic tools are: Can provide rapid GNR • Simple results (eg. at-home GOLD NANOROD TECHNOLOGY • Fast pregnancy tests) at • Low-cost point-of-care • Rely on nanoparticles How could Sona’s GNRs make a difference? • Multiple test lines per unit GNR- B
Slide 17: Sona's Bovine Tuberculosis Test
Sona’s “With help from the NRC IRAP program and the collaboration with Bovine 17.7m our partners in the UK, we hope to offer farmers a more effective method for early detection of bovine TB than Tuberculosis BOVINE TB TESTING EVENTS PY IN UK13 is currently used to mitigate the spread of this debilit
Slide 18: Sona's Concussion Screening Test
Sona’s Concussion 10m “We estimate that between 1.1 and 1.9 million sports and Screening Test CONCUSSIONS PY 7 recreation related concussions occur annually in US children aged ≤18 years.” Prototype American Academy of Pediatrics8 Current Problems Sona’s Concussion Screening Solution Biomarkers Othe
Slide 19: Management Team
Management Team David Regan Len Pagliaro, PhD Darren Rowles Kulbir Singh PhD Robert Randall, CPA CEO CSO Head of Diagnostics Co-Founder & Chief Financial Officer Head of GNR R&D o Business and commercial o Prof. of Bioengineering & o 17 years' experience with o Responsible for GNR o Extensive public
Slide 20: Board of Directors and Advisory Board
Board of Directors Walter Strapps Neil Fraser Dr. Michael Gross James Megann Mark Lievonen Director Director Director Director Chair o CEO and co-founder, Carver o Past-president of Medtronic Canada o Past-president of Sanofi Pasteur Biosciences Inc., a Khosla Ventures o 25 years of experience in ve
Slide 21: Thank you
info@sonanano.com Purdy’s Wharf Tower II Suite 2001 – 1969 Upper Water Street Halifax, Nova Scotia, Canada B3J 3R7 +1 902 442 0653 BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Thank you David Regan CEO Sona Nanotech Inc. sonanano.com 21 CSE: SONA | OTCQB: SNANF
Slide 22: Appendix
APPENDIX
Slide 23: Appendix A: Sources in document
Appendix A Sources in document 1. Mousavi SM, Hashemi SA, Mazraedoost S, Yousefi K, Gholami A, Behbudi G, Ramakrishna S, Omidifar N, Alizadeh A, Chiang WH. Multifunctional Gold Nanorod for Therapeutic Applications and Pharmaceutical Delivery Considering Cellular Metabolic Responses, Oxidative Stress
Slide 24: Appendix B: Additional Reading
Appendix B Additional Reading Gold Nanorods Traumatic Brain Injury Gold nanorods as contrast agents for biological imaging: optical properties, surface conjugation and photothermal Injury in review, 2020 edition: Spotlight on traumatic brain injuries across the life course - effects Traumatic Brain
Sona Nanotech — Investor Presentation (September 2023) on 6ix